TD Cowen analyst Joseph Thome reiterated a Buy rating on Adverum Biotechnologies (NASDAQ: ADVM).The analyst commented, "ADVM reported a Q2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE